Article | May 14, 2026

Becoming A Cornerstone Of Fujifilm's CDMO Strategy In Denmark

By Christian Houborg, Senior Vice President and Denmark Site Head, FUJIFILM Biotechnologies

GettyImages-1585548490-modular-facility-laboratory-drug-development

Denmark’s Hillerød biomanufacturing site offers a case study in how legacy facilities can be reimagined to meet the speed, scale, and complexity demanded by modern biologics. Shaped by a strong manufacturing culture and a deliberate shift toward partnership, the site has evolved into a modular, interoperable hub designed for seamless tech transfer and global consistency. Its expansion strategy emphasizes standardized equipment, digitalized operations, and parallel site development, reducing timelines while maintaining regulatory rigor. Large-scale monoclonal antibody production remains a core strength, complemented by network-wide specialization in advanced modalities. Digital tools such as real-time process monitoring and AI-enabled quality systems are reframing compliance as a driver of operational excellence rather than a constraint. Sustainability is embedded at an infrastructure level, with electrification, renewable energy sourcing, and heat recovery integrated into growth plans. Together, these elements illustrate how industrialized biomanufacturing can support innovators seeking reliable, end-to-end manufacturing without building their own facilities.

Access the full article for a closer look at the strategy, milestones, and thinking behind this transformation.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma